For research use only. Not for therapeutic Use.
Disitamab（Cat No.:I042081）is an investigational monoclonal antibody targeting HER2 (human epidermal growth factor receptor 2), a protein overexpressed in certain cancers, including breast and gastric cancer. By binding to HER2, disitamab aims to inhibit tumor cell growth and proliferation, triggering immune responses that help eliminate cancer cells. It is being studied in clinical trials for its effectiveness as a treatment for HER2-positive cancers, both as a monotherapy and in combination with other therapies. The ongoing trials are focused on evaluating its safety, efficacy, and potential to improve outcomes in patients with HER2-driven cancers.
| Catalog Number | I042081 |
| CAS Number | 2185868-98-6 |
| Purity | ≥95% |
